Rogaratinib

DB15078InvestigationalSmall molecule

Rogaratinib is under investigation in clinical trial NCT03762122 (Rogaratinib in Patients With Advanced Pretreated Squamous-cell Non-small Cell Lung Cancer (SQCLC)).

Mechanism: Pharmacologically active on Fibroblast growth factor receptor 1, Fibroblast growth factor receptor, and Fibroblast growth factor receptor 2
Curator reviewed
Formula / weight: C₂₃H₂₆N₆O₃S · 466.56 g/mol (avg)
Code names: BAY-1163877

Resolves to

Compound

UNII98BSN6N516CAS1443530-05-9ChEMBLCHEMBL3963485

Structure

InChIKeyHNLRRJSKGXOYNO-UHFFFAOYSA-NSMILESCOCC1=C(CN2CCNC(=O)C2)N2N=CN=C(N)C2=C1C1=CC2=C(S1)C(OC)=CC(C)=C2

Targets

P11362FGFR1P21802FGFR2P22607FGFR3P22455FGFR4

What you can answer from here — as of September 16, 2026

5Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

10Clinical trialsPhase, status and sponsor resolved per trial

10+ReferencesStructured and connected to the statements they support

Which drugs share a target with Rogaratinib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account